News
TXMD
1.220
-2.42%
-0.030
Weekly Report: what happened at TXMD last week (1202-1206)?
Weekly Report · 4d ago
Weekly Report: what happened at TXMD last week (1125-1129)?
Weekly Report · 12/02 09:27
Weekly Report: what happened at TXMD last week (1118-1122)?
Weekly Report · 11/25 09:25
Weekly Report: what happened at TXMD last week (1111-1115)?
Weekly Report · 11/18 09:25
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
TipRanks · 11/13 04:48
Therapeutics MD GAAP EPS of -$0.05
Seeking Alpha · 11/12 23:14
TherapeuticsMD Shifts Focus with Lower Q3 Losses
TipRanks · 11/12 22:04
THERAPEUTICSMD INC: QTRLY SHR LOSS FROM CONT OPS $0.05
Reuters · 11/12 21:05
Press Release: TherapeuticsMD Announces Third Quarter 2024 Financial Results
Dow Jones · 11/12 21:05
Weekly Report: what happened at TXMD last week (1104-1108)?
Weekly Report · 11/11 09:27
Weekly Report: what happened at TXMD last week (1028-1101)?
Weekly Report · 11/04 09:27
Weekly Report: what happened at TXMD last week (1021-1025)?
Weekly Report · 10/28 09:25
Weekly Report: what happened at TXMD last week (1014-1018)?
Weekly Report · 10/21 09:25
Weekly Report: what happened at TXMD last week (1007-1011)?
Weekly Report · 10/14 09:30
Weekly Report: what happened at TXMD last week (0930-1004)?
Weekly Report · 10/07 09:28
Weekly Report: what happened at TXMD last week (0923-0927)?
Weekly Report · 09/30 09:27
Weekly Report: what happened at TXMD last week (0916-0920)?
Weekly Report · 09/23 09:26
Weekly Report: what happened at TXMD last week (0909-0913)?
Weekly Report · 09/16 09:24
Weekly Report: what happened at TXMD last week (0902-0906)?
Weekly Report · 09/09 09:26
Weekly Report: what happened at TXMD last week (0826-0830)?
Weekly Report · 09/02 09:27
More
Webull provides a variety of real-time TXMD stock news. You can receive the latest news about Therapeuticsmd Inc through multiple platforms. This information may help you make smarter investment decisions.
About TXMD
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).